Capital World Investors Altimmune, Inc. Transaction History

Capital World Investors

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$8.43 - $16.81 $5.84 Million - $11.6 Million	-692,604 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$9.85 - $16.46 $7.01 Million - $11.7 Million	-711,396 Reduced 50.67%	692,604 $6.82 Million
Q4 2020 Feb 12, 2021	BUY	$7.84 - $14.22 $4.26 Million - $7.72 Million	543,000 Added 63.07%	1,404,000 $15.8 Million
Q3 2020 Nov 13, 2020	BUY	$9.93 - $33.26 $8.55 Million - $28.6 Million	861,000 New	861,000 $11.4 Million

208

39.5M

1.94M

1.38M

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $315M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Capital World Investors, based on Form 13F filings with the SEC.

Stay updated on Capital World Investors with notifications on news.